

Corporate Profile

Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

Stock Performance

CPH (Common Stock)

Exchange	TSX (Canadian Dollar)
Price	Can\$2.96
Change (%)	▼ 0.06 (1.99%)
Volume	120,450
52 Week Low	Can\$2.65
Market Cap	Can\$80,872,580
Rolling EPS	0.43
PE Ratio	6.97
Shares Outstanding	26,779,000

Data as of 10/19/18 3:59 p.m. ET



Recent Headlines & Events

02/28/18 - 7:00 a.m.
 Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® from Synergy Pharmaceuticals

06/02/17 - 7:00 a.m.
 Cipher Pharmaceuticals Adds New Vice President of Corporate Development

05/12/17 - 10:35 a.m.
 Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders

There are currently no events scheduled.

Analyst Estimates / Ratings

Unable to fulfill request.

SEC Filings

Filing Date	Form
02/22/17	15-12B/A
01/17/17	15-12B
01/03/17	6-K
12/21/16	S-8 POS

Corporate Governance

Shawn Patrick O'Brien	President & CEO
Norman Evans, CA	Chief Financial Officer
Ralph Boher	President & General Manager, United States
Joan Chyphyha	President and General Manager, Canada
Brian Rosenberger	Vice President, Alliance and Strategic Portfolio Management
Linda Angaritis	Vice President, Global Regulatory Compliance and Quality
Lynne Bulger	VP Global Medical and Clinical Affairs
Peter Weiler	Vice President, Business Development
Mark Spina, CPA	Senior Vice President, Finance and Treasury
Chuck Jenkins	Vice President, Marketing, United States
Daniel B. Ward, Jr., M.D., FAAD	Medical Director, United States

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	17	37.68	53.7	14,354,560
Mutual Fund	7	4.34	7.3	1,954,393
Insider *	8	2.30	3.1	838,649

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Mull (John D M.D.)	9,821,265	36.8	20,000	06/28/18
Montrusco Bolton Investments Inc.	1,575,733	5.9	1,575,733	07/31/17
Grandeur Peak Global Advisors, LLC	1,522,200	5.7	1,522,200	04/30/18
CHS Asset Management Inc.	571,104	2.1	571,104	06/30/17
Taylor Asset Management Inc.	243,100	0.9	0	06/30/18
Next Edge Capital Corp.	180,000	0.7	89,600	06/30/18
Wolkin (Harold Morton)	122,662	0.5	4,237	09/17/18
Deboeck (Arthur Marie Joseph Ghislain)	102,800	0.4	0	03/29/18
Beaudet (Mark A)	73,989	0.3	6,293	09/17/18
Godin (Christian)	35,251	0.1	2,984	09/17/18

Data provided by Nasdaq. Minimum 15 minutes delayed.